Evidence map›Paper›PMID 35207255›Full record

ArticleJournal of clinical medicine2022

Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia.

Genovefa Kolovou, Vana Kolovou, Niki Katsiki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Plozasiran: a small interfering RNA therapy for hypertriglyceridemia and familial chylomicronemia syndrome.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Genovefa KolovouMetropolitan Hospital, Cardiometabolic Center, Lipoprotein Apheresis and Lipid Disorders Clinic, 9 Ethn. Makariou & 1 El Venizelou Str., N Faliro, 185 47 Athens, Greece.
Vana KolovouMetropolitan Hospital, Cardiometabolic Center, Lipoprotein Apheresis and Lipid Disorders Clinic, 9 Ethn. Makariou & 1 El Venizelou Str., N Faliro, 185 47 Athens, Greece.
Niki KatsikiFirst Department of Internal Medicine, Diabetes Center, Division of Endocrinology and Metabolism, AHEPA University Hospital, 541 24 Thessaloniki, Greece.ORCID 0000-0003-0894-2644
Metropolitan Hospital · GRAHEPA University Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFamilial chylomicronemia syndrome (FCS) is a rare inherited disease, mainly due to lipoprotein lipase (

Indexed as

familial chylomicronemia syndromehypertriglyceridemialipoprotein lipase mutationpancreatitisvolanesorsen

Identifiers

PMID35207255
PMCPMC8880470
OpenAlexW4212956691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.